US Patent 7960522 Certain aminoalkyl glucosaminide phosphate compounds and their use
Patent 7960522 was granted and assigned to Corixa on June, 2011 by the United States Patent and Trademark Office.
All edits
Edits on 24 Apr, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 28 Nov, 2023
Golden AI
Edits made to:
Article (+322 characters)
Article
Patent abstract
Compounds that are adjuvants and immunoeffectors are described and claimed. The compounds augment antibody production in immunized animals as well as stimulate cytokine production and activate macrophages. Compositions and methods for using the compounds as adjuvants and immunoeffectors are also disclosed.
Edits on 18 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07960522 Certain aminoalkyl glucosaminide phosphate compounds and their use US Patent 7960522 Certain aminoalkyl glucosaminide phosphate compounds and their use
Infobox
Patent Number
0796052200
Patent Number
796052200
Edits on 25 Mar, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
079605220
Date of Patent
June 14, 2011
0Patent Application Number
108886830
Date Filed
July 8, 2004
0Patent Primary Examiner
Edits on 28 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
079605220
Date of Patent
June 14, 2011
0Patent Application Number
108886830
Date Filed
July 8, 2004
0Patent Primary Examiner
Edits on 7 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07960522 Certain aminoalkyl glucosaminide phosphate compounds and their use
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07960522
Date of patent
June 14, 2011
Patent application number
10888683
Date Filed
July 8, 2004
Patent primary examiner
Find more entities like US Patent 7960522 Certain aminoalkyl glucosaminide phosphate compounds and their use
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.